Immune modulatory activity of human ribonucleases

• US 20040009503A1
• Filed: 03/26/2003
• Published: 01/15/2004
• Est. Priority Date: 07/03/2002
• Status: Abandoned Application

• Current Assignee: Pathway Diagnostics Corporation, Inc.
• Original Assignee: Molecular Staging Inc. (Qiagen NV)
• Inventors: Satyaraj, Ebenezer, Fu, Qin, Schweitzer, Barry, Patel, Dhavalkumar D., Kingsmore, Stephen F., Tchernev, Velizar
• Application Number:
  US10/396,317
• Publication Number:
  US 20040009503A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61K 2039/55516 Proteins; Peptides
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: G01N 2333/922 Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
• CPC Class Codes: G01N 33/573 for enzymes or isoenzymes

Abstract

Human extracellular ribonucleases (RNases) are widely distributed in various organs and body fluids and together with other members of the mammalian RNase A superfamily. In addition to their RNase activity, several RNases have been shown to have special biological actions, i.e., antitumor, antiviral and angiogenic properties. However, the molecular mechanisms of such activities are unclear. Using protein microarrays amplified rolling circle amplification (RCA), we investigated the effects of EDN (Rnase 2), ECP (Rnase 3) and RNase 1 on leukocytes cytokine production. We measured the levels of 78 different cytokines and growth factors in culture supernatants to determine the cytokine profiles of cells treated with different combinations of RNases and RNase inhibitors. Members of human ribonuclease family (such as Rnase 1, hEDN (Rnase 2) and Rnase 3) induced expression of certain sets of cytokines in human leukocytes, including ENA-78, EOT2, BLC, GDNF, 1309, IFN-α, IFN-γ, IL-10, IL-12P40, IL-12p70, IL-13, IL-16, IL-18, IL-1β, IL-1ra, IL-2Sra, IL-3, IL-6, IL-6sR, IL-7, IL-8, IP-10, MCP-1, MCP-2, MCP-3, MCSF, MIG, MDC, MIP-1α, MIP-1β, MPIF-1, NAP-2, RANTES, sCD23, OSM, TARC, TNF-α, TNF-R1 and uPAR. Thus members of the Rnase superfamily are therapeutic targets for treatment of inflammatory diseases and clinical conditions. Inhibition or augmentation of Rnase expression is used to modulate the immune system and is beneficial for host defense against various diseases and is exploited as an adjuvant. The expression of Rnases is a diagnostic marker for inflammation related conditions and is used to determine various disease stages. In addition, expression of cytokines, chemokines, growth factors is used to monitor efficacy of Rnase-base therapies.

Claims

1. A method of diagnosing an inflammatory syndrome in a patient, comprising:

determining in a test sample from a patient amount of one or more Rnases; and

comparing the amount to an average amount found in a control sample of a population of healthy humans, wherein an increased amount in the test sample relative to the average amount indicates an inflammatory syndrome in the patient.

2. The method of claim 1 wherein the syndrome is sepsis.

3. The method of claim 1 wherein the syndrome is cardiovascular disease.

4. The method of claim 1 wherein the syndrome is an infectious disease.

5. The method of claim 1 wherein the syndrome is an autoimmune disease.

6. The method of claim 1 wherein the syndrome is cancer.

7. The method of claim 1 wherein the syndrome is acute and/or chronic inflammation.

8. The method of claim 1 wherein the syndrome is rheumatoid arthritis.

9. The method of claim 1 wherein the syndrome is multiple organ failure.

10. The method of claim 1 wherein the syndrome is acute respiratory distress syndrome (ARDS).

11. The method of claim 1 wherein the syndrome is psoriasis.

12. The method of claim 1 wherein the syndrome is lupus.

13. The method of claim 1 wherein the syndrome is inflammatory bowel disease.

14. The method of claim 1 wherein the test sample is selected from the group consisting of serum, plasma, lymph fluid, peripheral lymphatic tissue, and blood.

15. The method of claim 1 wherein the test sample comprises dendritic cells.

16. The method of claim 1 wherein the test sample comprises Langerhans cells.

17. The method of claim 1 wherein the test sample comprises monocytes.

18. The method of claim 1 wherein an increased amount is at least two-fold more in the test sample than in the control sample.

19. The method of claim 1 wherein an increased amount is at least three-fold more in the test sample than in the control sample.

20. The method of claim 1 wherein an increased amount is at least four-fold more in the test sample than in the control sample.

21. The method of claim 1 wherein said step of determining employs an array of a first set of antibodies for capturing said one or more Rnases.

22. The method of claim 21 wherein said step of determining employs a second set of antibodies which is applied to the array after binding of Rnases in the test sample to the first set of antibodies.

23. The method of claim 22 wherein said second set of antibodies comprises covalently attached oligonucleotides.

24. The method of claim 22 wherein a third set of antibodies is applied to the array which specifically bind to the second set of antibodies.

25. The method of claim 24 wherein the third set of antibodies comprises covalently attached oligonucleotides.

26. The method of claim 23 wherein rolling circle amplification is performed using said oligonucleotides as primers.

27. The method of claim 25 wherein rolling circle amplification is performed using said oligonucleotides as primers.

28. A method of treating a patient with an inflammatory syndrome, comprising:

administering to a patient with an inflammatory syndrome one or more specific inhibitory molecules selected from the group consisting of antibodies and antisense RNA, wherein said specific inhibitory molecules specifically bind to and inhibit a human Rnase.

29. The method of claim 28 wherein the syndrome is sepsis.

30. The method of claim 28 wherein the syndrome is cardiovascular disease.

31. The method of claim 28 wherein the syndrome is an infectious disease.

32. The method of claim 28 wherein the syndrome is an autoimmune disease.

33. The method of claim 28 wherein the syndrome is cancer.

34. The method of claim 28 wherein the syndrome is acute and/or chronic inflammation.

35. The method of claim 28 wherein the syndrome is rheumatoid arthritis.

36. The method of claim 28 wherein the syndrome is multiple organ failure.

37. The method of claim 28 wherein the syndrome is acute respiratory distress syndrome (ARDS).

38. The method of claim 28 wherein the syndrome is psoriasis.

39. The method of claim 28 wherein the syndrome is lupus.

40. The method of claim 28 wherein the syndrome is inflammatory bowel disease.

41. The method of claim 28 wherein the syndrome is organ or tissue transplant rejection.

42. The method of claim 28 wherein the specific inhibitory molecules are antibodies.

43. The method of claim 28 wherein the specific inhibitory molecules are monoclonal antibodies.

44. The method of claim 31 wherein the specific inhibitory molecules are a cocktail of monoclonal antibodies.

45. A method of preventing an inflammatory syndrome in a patient, comprising:

administering to an organ or tissue transplant patient at risk of developing an inflammatory syndrome, one or more specific inhibitory molecules selected from the group consisting of antibodies and antisense RNA, wherein said specific inhibitory molecules specifically bind to and inhibit a human Rnase.

46. A method of stimulating an immune response comprising:

administering a human Rnase to a subject in need of an augmented immune response, whereby the subject'"'"'s immune response is increased.

47. The method of claim 46 wherein the subject is a vaccine recipient.

48. The method of claim 46 wherein the subject has received immune response depressing drugs or therapy.

49. The method of claim 47 wherein the vaccine and the Rnase are administered simultaneously.

50. A composition for vaccinating a human comprising:

an immunogenic antigen; and

a human Rnase.

51. A method to monitor the effects of Rnase therapy or anti-Rnase therapy, comprising:

(a) measuring amount of one or more protein selected from the group consisting of ENA-78, EOT2, BLC, GDNF, 1309, IFN-α

, IFN-γ

, IL-10, IL-12P40, IL-12p70, IL-13, IL-16, IL-18, IL-1β

, IL-Ira, IL-2Sra, IL-3, IL-6, IL-6sR, IL-7, IL-8, IP-10, MCP-1, MCP-2, MCP-3, MCSF, MIG, MDC, MIP-1α

, MIP-1β

, MPIF-1, NAP-2, RANTES, sCD23, OSM, TARC, TNF-α

, TNF-R1, uPAR, and fragments thereof in a sample collected from a patient at a first time;

(b) repeating step (a) in a sample collected from the patient at a later time;

(c) comparing the amounts measured in step (a) and in step (b), wherein an increased amount over time denotes an effect of an Rnase and a decreased amount denotes an effect of an anti-Rnase therapy.

52. A method of treating a patient with an inflammatory syndrome, comprising:

administering to a patient with an inflammatory syndrome one or more specific inhibitory molecules which specifically bind to a cellular receptor for a human Rnase, thereby blocking the human Rnase from binding to the cellular receptor.

53. The method of claim 52 wherein the syndrome is sepsis.

54. The method of claim 52 wherein the syndrome is cardiovascular disease.

55. The method of claim 52 wherein the syndrome is an infectious disease.

56. The method of claim 52 wherein the syndrome is an autoimmune disease.

57. The method of claim 52 wherein the syndrome is cancer.

58. The method of claim 52 wherein the syndrome is acute and/or chronic inflammation.

59. The method of claim 52 wherein the syndrome is rheumatoid arthritis.

60. The method of claim 52 wherein the syndrome is multiple organ failure.

61. The method of claim 52 wherein the syndrome is acute respiratory distress syndrome (ARDS).

62. The method of claim 52 wherein the syndrome is psoriasis.

63. The method of claim 52 wherein the syndrome is lupus.

64. The method of claim 52 wherein the syndrome is inflammatory bowel disease.

65. The method of claim 52 wherein the syndrome is organ or tissue transplant rejection.

66. The method of claim 52 wherein the specific inhibitory molecule is protamine.

67. The method of claim 52 wherein the specific inhibitory molecule is polylysine.

68. The method of claim 52 wherein the specific inhibitory molecule is heparin.